Abbott Laboratories (ABT) : Founders Financial Securities reduced its stake in Abbott Laboratories by 0.34% during the most recent quarter end. The investment management company now holds a total of 85,459 shares of Abbott Laboratories which is valued at $3,579,878 after selling 293 shares in Abbott Laboratories , the firm said in a disclosure report filed with the SEC on Jul 8, 2016.Abbott Laboratories makes up approximately 1.63% of Founders Financial Securities’s portfolio.
Other Hedge Funds, Including , Next Financial Group Inc boosted its stake in ABT in the latest quarter, The investment management firm added 660 additional shares and now holds a total of 15,955 shares of Abbott Laboratories which is valued at $668,355. Abbott Laboratories makes up approx 0.21% of Next Financial Group Inc’s portfolio.Raymond James Trust N.a. boosted its stake in ABT in the latest quarter, The investment management firm added 7,364 additional shares and now holds a total of 153,168 shares of Abbott Laboratories which is valued at $6,416,208. Abbott Laboratories makes up approx 0.54% of Raymond James Trust N.a.’s portfolio.Osborn Rohs Williams Donohoe Ltd boosted its stake in ABT in the latest quarter, The investment management firm added 3,151 additional shares and now holds a total of 142,903 shares of Abbott Laboratories which is valued at $5,986,207. Abbott Laboratories makes up approx 1.15% of Osborn Rohs Williams Donohoe Ltd’s portfolio.Toth Financial Advisory Corp reduced its stake in ABT by selling 3,187 shares or 2.25% in the most recent quarter. The Hedge Fund company now holds 138,352 shares of ABT which is valued at $5,470,438. Abbott Laboratories makes up approx 1.67% of Toth Financial Advisory Corp’s portfolio.
Abbott Laboratories closed down -0.24 points or -0.57% at $41.97 with 79,20,234 shares getting traded on Wednesday. Post opening the session at $42.24, the shares hit an intraday low of $41.85 and an intraday high of $42.515 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Abbott Laboratories reported $0.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Apr 20, 2016. Analyst had a consensus of $0.39. The company had revenue of $4885.00 million for the quarter, compared to analysts expectations of $4777.68 million. The company’s revenue was down -.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.47 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016. Company shares were Reiterated by RBC Capital Mkts on Apr 11, 2016 to “Outperform”, Firm has raised the Price Target to $ 48 from a previous price target of $45 .
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.